2.1 | | ELK1 | 'Mycobacterium tuberculosis' vs 'none' in 'infant' | developmental stage, infect | Multifaceted dysfunction of infant airway macrophages in response to Mycobacterium tuberculosis |
2 | | ELK1 | 'CD3/CD28 beads' vs 'none' in 'none' | stimulus, xenograft | RNA-Seq of T cells sorted from human PBMCs, or from T cells stimulated with CD3/CD28 beads for 4 days, or from the spleen of NSG or NSG-HLA-A2/HHD mice, 7 days after transplantation with human PBMCs |
2 | | ELK1 | 'lipopolysaccharide' vs 'none' in 'systemic-onset juvenile idiopathic arthritis' | disease, stimulus | A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis [RNA-Seq] |
1.9 | | ELK1 | 'EX00000246; stimulated with interferon gamma and lipopolysaccharide' vs 'none' at '24 hour' | compound, time, treatment | GPBAR1 agonism has a broad impact on blocking macrophage activation |
1.9 | | ELK1 | 'squamous cell carcinoma' vs 'normal' | block, disease | RNA-seq of a panel of non-melanoma skin cancer lesions |
1.9 | | ELK1 | 'estrogen receptor alpha shRNA' vs 'scrambled shRNA' | RNA interference | RNA-seq of the human breast cancer ERα-suppressed MCF-7(MCF-7/SP10+) cells and of their internal control MCF-7 (MCF-7/C) cells |
-1.9 | | ELK1 | 'P-bodies (cytosolic RNP granules)' vs 'pre-sorted fraction' | fraction | RNA-Seq of purified P-bodies from HEK293 cells |
1.9 | | ELK1 | 'cerebral edema' vs 'control' | clinical history | Detection of potential neuroprotective changes at the molecular, anatomical and physiological level in identified human pyramidal cells in response to brain edema and increased intracranial pressure. |
1.8 | | ELK1 | 'actinic keratosis' vs 'normal' | block, disease | RNA-seq of a panel of non-melanoma skin cancer lesions |
1.8 | | ELK1 | 'lipopolysaccharide' vs 'none' in 'normal' | disease, stimulus | A multidimensional blood stimulation assay reveals immune alterations underlying systemic juvenile idiopathic arthritis [RNA-Seq] |
1.7 | | ELK1 | 'dexamethasone; 1 micromolar' vs 'ethanol' | compound | RNA-seq in GR18 cell line to identify genes regulated by the Glucocorticoid Receptor |
1.7 | | ELK1 | 'sebaceous of Jadassohn nevus' vs 'normal' | block, disease | RNA-seq of a panel of non-melanoma skin cancer lesions |
-1.7 | | ELK1 | 'Zaire ebolavirus lacking the mucin domain of GP' vs 'mock' at '8 hour' | infect, time | Human U937 cell transcriptome response to Zaire Ebola virus wild-type in the delta-VP30 background and delta-mucin virus |
1.6 | | ELK1 | '24 hour' vs '0 hour' in 'MCF-10A' | cell line, time | Knock-in of PIK3CA-H1047R into MCF-10A |
-1.6 | | ELK1 | 'TDP-43 knock-down' vs 'control' | genotype | 3'-end targeted sequencing of 6 control and 6 TDP-43 KD samples in HEK293 |
1.6 | | ELK1 | 'lipopolysaccharide; 10 nanogram per milliliter' vs 'none' | compound | Transcription profiling by high throughput sequencing of human monocytes treated with lipopolysaccharide |
1.6 | | ELK1 | 'Francisella tularensis novicida' vs 'uninfected' | infect | Transcription profiling by array of human peripheral blood mononuclear cells infected with Francisella tularensis |
1.5 | | ELK1 | 'dexamethasone; 1 micromolar' vs 'vehicle' | compound | RNA-seq in GR18 cell line to identify genes regulated by the Glucocorticoid Receptor (24h treatment) |
1.5 | | ELK1 | 'DMSO' in 'stimulated with interferon gamma and lipopolysaccharide' vs 'none' at '24 hour' | compound, time, treatment | GPBAR1 agonism has a broad impact on blocking macrophage activation |
1.5 | | ELK1 | 'neoplasm' vs 'normal tissue adjacent to neoplasm' | sampling site | Global gene expression profiles of 10 gastric cancer (GC) samples and 10 gastric normal adjacent tissue (gNAT) samples |
-1.5 | | ELK1 | 'atopic eczema; normal skin' vs 'normal; normal skin' | clinical information, disease, phenotype | Transcription profiling by array of acute and chronic atopic dermatitis compared to normal skin |
-1.4 | | ELK1 | 'siRNA double knockdown of HNF4A and GATA6' vs 'scrambled siRNA' | RNA interference | Total RNA-seq of human oesophageal adenocarcinoma cell line OE19 treated with siNT, siHNF4A, siGATA6 and siHNF4A+siGATA6 for 72 hours |
-1.4 | | ELK1 | 'glioblastoma' vs 'control' | block, disease | DNA Methylation Profiling of Glioblastoma: Impact on Gene Expression and Clinical Outcome (Agilent Expression Study) |
1.3 | | ELK1 | 'DMSO' in 'stimulated with interferon gamma and lipopolysaccharide' vs 'none' at '6 hour' | compound, time, treatment | GPBAR1 agonism has a broad impact on blocking macrophage activation |
1.3 | | ELK1 | 'EX00000246' vs 'none' in 'unstimulated' at '24 hour' | compound, time, treatment | GPBAR1 agonism has a broad impact on blocking macrophage activation |
1.3 | | ELK1 | 'Mycobacterium tuberculosis' vs 'none' in 'adult' | developmental stage, infect | Multifaceted dysfunction of infant airway macrophages in response to Mycobacterium tuberculosis |
-1.3 | | ELK1 | 'IGA glomerulonephritis' vs 'normal' | disease | Transcriptomic and proteomic profiling reveal insights of mesangial cell function in patients with IgA Nephropathy |
1.3 | | ELK1 | 'myeloid-related protein 8' vs 'control' on 'Affymetrix GeneChip Human Genome U133 Plus 2.0 [HG-U133_Plus_2]' | stimulus | Transcription profiling by array of human blood monocyte stimulated with various stimuli (control, MRP8, LPS, TNF, IL1) to study signalling pathways in phagocytic activation |
1.3 | | ELK1 | 'dexamethasone; 100 nanomolar' vs 'ethanol; 0.1 percent' | compound | Expression profile of A1-2 cells treated with 100 nM Dexamethasone or ethanol vehicle for 8h |
1.2 | | ELK1 | 'heat-killed Escherichia coli' vs 'none' in 'ulcerative colitis' | disease, stimulus | Transcription profiling by array of primary human macrophages cultured from patients with ulcerative colitis or healthy individuals with or without stimulation by heat-killed E. coli |
-1.2 | | ELK1 | 'doxycycline; 0.5 microgram per milliliter; Day 4 post Neurogenin induction' vs 'control' | compound, treatment | Rapid neurogenesis through transcriptional activation in human stem cell (RNA-Seq) |
1.2 | | ELK1 | 'Staphylococcus aureus strain SK2' vs 'none' | infect | Transcription profiling of human primary bone cells exposed to Staphylococcus aureus |
-1.2 | | ELK1 | 'HER2 Positive Breast Carcinoma; breast carcinoma' vs 'normal' | clinical information, disease | RNA-seq of 17 breast tumor samples of three different subtypes and normal human breast organoids samples |
-1.2 | | ELK1 | 'metastatic melanoma; responder' vs 'normal; not applicable' | disease, response to treatment | Bulk RNA-seq validation experiment comparing blood from healthy donors and two groups of metastatic melanoma patients: responders and non-responders to anti-PD-1 immunotherapy |
1.1 | | ELK1 | 'heat-killed Escherichia coli' vs 'none' in 'normal' | disease, stimulus | Transcription profiling by array of primary human macrophages cultured from patients with ulcerative colitis or healthy individuals with or without stimulation by heat-killed E. coli |
1.1 | | ELK1 | 'uterine leiomyosarcoma' vs 'normal' | disease | Identification of driver genes in uterine leiomyosarcoma: RNA seq |
1 | | ELK1 | 'lipopolysaccharide; 20 nanogram per milliliter; stimulated; 2 hour' vs 'none; unstimulated; 24 hour' | compound, stimulus, time | Genetics of gene expression across innate immune stimulation in primary monocytes |
1 | | ELK1 | 'colon adenocarcinoma' vs 'normal' | disease | RNA-seq of 21 sessile serrated colon adenoma/polyps, 10 hyperplastic polyps, 10 adenomas, 21 uninvolved colon and 20 control colon specimens |
1 | | ELK1 | 'Human gammaherpesvirus 4' at '3 day' vs 'none' at '0 day' | infect, time | Infection of naïve primary human B-lymphocytes with Epstein-Barr virus (EBV) – time course transcriptomic analysis in the pre-latent phase of viral infection |
-1 | | ELK1 | 'doxycycline; 0.5 microgram per milliliter; Day 3 post Neurogenin induction' vs 'control' | compound, treatment | Rapid neurogenesis through transcriptional activation in human stem cell (RNA-Seq) |
-1 | | ELK1 | 'contrast-enhancing core; glioma' vs 'normal' | biopsy site, disease | Transcription profiling by high throughput sequencing in the margins of glioblastoma |
1 | | ELK1 | 'Francisella tularensis Schu S4' vs 'uninfected' | infect | Transcription profiling by array of human peripheral blood mononuclear cells infected with Francisella tularensis |
1 | | ELK1 | 'expressing O6-methylguanine methyltransferase' vs 'control' | phenotype | MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib |
-1 | | ELK1 | 'non-triple-negative breast cancer; breast carcinoma' vs 'normal' | clinical information, disease | RNA-seq of 17 breast tumor samples of three different subtypes and normal human breast organoids samples |
1 | | ELK1 | 'lipopolysaccharide' vs 'control' on 'Affymetrix GeneChip Human Genome HG-U133A [HG-U133A]' | stimulus | Transcription profiling by array of human blood monocyte stimulated with various stimuli (control, MRP8, LPS, TNF, IL1) to study signalling pathways in phagocytic activation |
-1 | | ELK1 | 'DICERER5/EX5; tunicamycin' vs 'DICERER5/EX5; control' | genotype, treatment | Induction of ER stress in HCT116 colon cancer cells |
-1 | | ELK1 | 'triple-negative breast cancer; breast carcinoma' vs 'normal' | clinical information, disease | RNA-seq of 17 breast tumor samples of three different subtypes and normal human breast organoids samples |
-1 | | ELK1 | 'astrocytoma' vs 'normal' | disease | Transcription profiling of human grade II astrocytic tumor (astrocytomas) vs grade IV tumors (glioblastoma) |
